Macrogenics Inc. MGNX
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Macrogenics Inc. (MGNX) is a healthcare company listed in the US with a market value of about $141M. In the twelve months to September 30, 2026 it had revenue of $141M and net income of -$51M, a net margin of -36.6%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 7% a year, a 5-year average ROIC of -71%.
About Macrogenics
Macrogenics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $48M in 2014 to $150M in 2025, growth of about 10.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 98% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141M | $150M | $150M | $59M | $152M | $77M | $105M | $64M | $60M | $158M | $92M |
| Net income | -$51M | -$75M | -$67M | -$9M | -$120M | -$202M | -$130M | -$152M | -$171M | -$20M | -$59M |
| Free cash flow | -$41M | -$83M | -$72M | -$80M | -$91M | -$150M | -$118M | -$139M | -$178M | -$15M | -$55M |
| EPS (diluted) | $-0.81 | $-1.18 | $-1.07 | $-0.15 | $-1.95 | $-3.37 | $-2.47 | $-0.62 | $-1.06 | $-0.54 | $-1.00 |
| Net margin | -36.6% | -49.9% | -44.7% | -15.4% | -78.8% | -261.0% | -123.7% | -236.5% | -285.2% | -12.4% | -63.7% |
| ROIC | — | -78.2% | -56.9% | -90.2% | -68.7% | -60.4% | -31.8% | -53.6% | -50.0% | -5.9% | -17.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $8.00, 264% above the current price; targets range from $4.00 to $11.00; the consensus rating is “Buy”; expected EPS is $-2.47 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Macrogenics pay a dividend?
Not currently.
Is Macrogenics a good stock to buy?
We do not give buy or sell advice. Macrogenics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.